Cytochrome P4502C19 (CYP2C19) is an important drug-metabolizing enzyme involved in the biotransformation of, for example, proton pump inhibitors and antidepressants. Several in vivo studies have shown that the CYP2C19 activity is inhibited by oral contraceptives, which can cause important drug interactions. The underlying molecular mechanism has been suggested to be competitive inhibition. However, the results presented here indicate that estradiol derivatives down-regulate CYP2C19 expression via estrogen receptor (ER) ␣, which interacts with the newly identified ER-binding half site [estrogen response element (ERE)] at the position Ϫ151/Ϫ147 in the CYP2C19 promoter. In gene reporter experiments in Huh-7 hepatoma cells, the activity of the luciferase construct carrying a 1.6-kb long CYP2C19 promoter fragment cotransfected with ER␣ was down-regulated upon treatment with 17␤-estradiol (EE) or 17␣-ethinylestradiol (ETE) at half-maximum concentrations of 10 Ϫ7 and 10 Ϫ8 M, respectively. Mutations introduced into the ERE half site Ϫ151/Ϫ147 significantly inhibited these ligand-dependent effects. Electrophoretic mobility shift assays and quantitative chromatin immunoprecipitation experiments revealed that estrogen receptor ␣ binds to this element. A significant suppression of CYP2C19 transcription by female sex steroids was confirmed by reverse transcription polymerase chain reaction after hormonal treatment of human hepatocytes. Inhibition experiments using a stable human embryonic kidney 293 CYP2C19 cell line revealed competitive inhibition at much higher concentrations of EE and ETE compared with those required for transcriptional inhibition. These results indicate that both EE and ETE inhibit CYP2C19 expression via an ER␣-dependent regulatory pathway, thus providing a new insight into the molecular mechanism behind the inhibitory effect of oral contraceptives on CYP2C19 activity.
Introduction
Cytochrome P4502C19 (CYP2C19) is the main enzyme for the metabolism of many important drugs, including protein pump inhibitors such as omeprazole, diazepam, the antidepressant escitalopram, the platelet aggregation inhibitor clopidogrel, and the antimalaria drug proguanil (Desta et al., 2002; Kirchheiner et al., 2004; Klotz, 2009) . CYP2C19 is known to be polymorphically expressed, which strongly influences the effect of drug treatment efficacy (Sim et al., 2006) . The enzyme is mainly present in the liver and intestine (Klose et al., 1999; Lä pple et al., 2003; Wu et al., 2006) . In addition, its activity is also affected by different drugs, which may potentially lead to unwanted drug-drug interactions associated with a higher risk of drug side effects or with a failure of therapeutic efficacy (Ingelman-Sundberg et al., 2007; Ingelman-Sundberg, 2008) . Several reports have shown that oral contraceptive (OC) formulations substantially decrease CYP2C19 activity (Hä gg et al., 2001; Palovaara et al., 2003) . The mechanism behind this has been suggested to be drug-drug interactions at the enzyme active site (Laine et al., 2000) . A modulatory effect of exogenous female sex steroids is not only confirmed for CYP2C19 but has also been shown for the enzymes CYP2A6 and CYP2C9 in vitro and in vivo (Sand-berg et al., 2004; Benowitz et al., 2006; Higashi et al., 2007) . Despite the fact that, each year, approximately 70 million women worldwide take such pills (Belle et al., 2002) , the mechanism by which estrogen derivatives affect CYP2C19 activity has not been yet elucidated. Such regulation might be also important with respect to gender differences in drug metabolism as observed with other cytochrome P450 enzymes (Wolbold et al., 2003) .
17␣-Ethinylestradiol (ETE) and estradiol (EE) are the major estrogens used in oral contraceptives and hormone replacement therapy. In clinical use, these estrogens are commonly combined with progestins to obtain better hormonal cycle control . It has been shown that OCs double the area under the curve of the CYP2C19 substrate omeprazole and the metabolic ratio of mephenytoin (Tamminga et al., 1999; Hä gg et al., 2001) . Both substances are the most commonly used markers of CYP2C19 activity. The inhibiting effect on CYP2C19 activity has been demonstrated to be exerted by the OC compound 17␣-ethinylestradiol and not by progestins, which are also included in OC formulations (Palovaara et al., 2003) .
Estrogenic and antiestrogenic effects are mediated through two related estrogen receptors ER␣ and ER␤ (van de Stolpe et al., 2004) . The ERs exert their transcriptional control upon interaction of the active receptor dimer with specific DNA binding sites, such as classic estrogen responsive elements [EREs, consensus sequence 5Ј-AGGTCAnnnTGACCT-3Ј (Couse et al., 1997; Driscoll et al., 1998) or estrogen receptor binding half-sites (ERE-half-sites (van de Stolpe et al., 2004) ]. Antiestrogens can act as pure estrogen antagonists [e.g., ICI 182,780 (fulvestrant)] or as partial agonists (also known as agonists/antagonists or selective estrogen receptor modulators) such as tamoxifen, its potent metabolite 4-hydroxytamoxifen (4-OHT), or raloxifene (R), which exert tissue-selective estrogen-like effects. The mechanism by which these compounds induce tissue-and gene-dependent effects remains to be unraveled (Fournier et al., 2001) . In addition to the ligand dependent activation of ER␣, ligand-independent activation pathways of ER␣ (most likely through phosphorylation of the N terminus of the receptor) have been described previously (Ignar-Trowbridge et al., 1992 , 1996 The estrogen interaction with CYP2C19 might also be important for breast cancer and breast cancer treatment because persons carrying the CYP2C19*17 allele, which is more highly expressed than the wild-type allele (Sim et al., 2006) , are protected from breast cancer (Justenhoven et al., 2009) , and CYP2C19*17-carrying breast cancer patients have better prognosis after treatment with tamoxifen (Schroth et al., 2007) .
In the current study, we experimentally tested the hypothesis that the decline in CYP2C19 activity in women using steroid oral contraceptives is caused by a transcriptional down-regulation of CYP2C19 gene expression rather than direct steroid-CYP2C19 protein interaction. Indeed, results from different experimental approaches indicate that both EE and ETE are able to induce binding of ligand-activated ER␣ to the identified specific ERE consensus half-site within CYP2C19 promoter with the ensuing inhibition of CYP2C19 expression at physiological hormone concentrations, which are significantly lower than those required for competitive inhibition using stably CYP2C19 enzyme expressing cells.
Materials and Methods
Plasmid Constructs and Chemicals. A 1.6-kb long fragment of CYP2C19 5Ј-flanking region was subcloned into the MluI/XhoI site of pGL3basic vector (Promega, Madison, WI) upstream of the luciferase gene (construct 2C19wtϪ1.6kb; Table 1 , Fig. 1b) . A construct containing destructive mutations at the possible ERE half-site at position (Ϫ151/Ϫ147) was generated from the parental 2C19wtϪ1.6kb construct using GeneTailor Mutagenesis kit (Invitrogen) (construct 2C19mutϪ1.6kb Table 1 , Fig. 1b) .
The expression vector encoding human estrogen receptor ␣ (pSG5-hER␣) was a kind gift of Dr. P. Chambon (Strasbourg, France). The ER␣ insert was recloned into the EcoRI site of pcDNA3.1 empty vector (Invitrogen). Chemicals (17␣-ethinylestradiol, 17␤-estradiol, 4-hydroxytamoifen, raloxifene) were purchased from Sigma (St. Louis, MO).
Electrophoretic Mobility Shift Assay. Nuclear protein extracts were prepared from human-derived hepatoma cell lines Huh-7 and HepG2 as described previously with slight modifications (Dignam et al., 1983; Nakabayashi et al., 1991) . ER␣ was in vitrotranslated using pcDNA3.1/ERa vector in the TNT T7-Coupled Reticulocyte Lysate System (results shown in supplemental data) (Clontech, Mountain View, CA).
Three different double-stranded (ds) oligonucleotides comprising 30 bp of the CYP2C19 promoter in wild type or in mutated form at the putative ERE half-site were generated by annealing sense and antisense oligonucleotides (Table 1) . Double-stranded oligonucle- Mixtures with nuclear extract were preincubated at 37°C for 15 min followed by addition of the respective labeled double-stranded oligonucleotides. The complete mixture was incubated again at 37°C for 15 min. For competition experiments, 100-and 200-fold excess of the respective unlabeled double-stranded oligonucleotide was added to the probe before the addition of 32 P-labeled double-stranded oligonucleotides. For supershift experiments, 2 g of ER␣ or ER␤ antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was added to the binding reaction, and samples were incubated on ice for 45 min before the incubation with labeled oligonucleotides. Five microliters of loading buffer were added and protein-bound as well as unbound DNA was resolved on a 4% nondenaturing polyacrylamide gel. Dried gels were subjected to filmless autoradiographic analysis (BAS-1800; Fujifilm, Tokyo, Japan).
Transient Transfections. Huh-7 cells were grown at 37°C in a humidified atmosphere with 5% CO 2 in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin/ streptomycin (Invitrogen, Carlsbad, CA). One day before transient transfection, 2 ϫ 10 5 Huh-7 cells were plated into 12-well plates. Two micrograms of the pGL3basic expression vector CYP2C19-1.6kb (wildtype or mutated form) or pGl3basic were cotransfected with 0.5 g of human pcDNA3.1-ER␣ or 0.5 g of pcDNA3.1 empty vector (negative control). Transient transfections were carried out in plain medium using Lipofectamine 2000 (Invitrogen) as to manufacturer's recommendations. 24 h after transfection medium was replaced to complete medium and cells were treated (as indicated in each figure) with final concentrations of 10 Ϫ10 to 10 Ϫ6 M 4-OHT, R, EE, or ETE. Substrates were diluted in 95% ethanol (vehicle) and applied at a final concentration of 0.2% (v/v) vehicle per well. Cells were harvested and analyzed for luciferase activity 24 h after treatment. In each transfection mixture, 6 ng of pRL-TK vector (Promega) was included as an internal control for transfection efficiency. Luciferase activity is expressed, therefore, as a ratio of firefly luciferase activity (in arbitrary units) to the corresponding activity of the pRL-TK. All experiments were performed in triplicate and repeated three times. ChIP Analysis. The assay was carried out using chromatin immunoprecipitation (ChIP) assay kit (Active Motif Inc., Carlsbad, CA) according to the manufacturer's protocol. In summary, Huh7 cells were grown to 80% confluence in two 75-cm 2 flasks for each treatment. Proteins were cross-linked in 1% formaldehyde, washed with phosphate-buffered saline, fixed in glycine solution, and scraped into 2 ml of phosphate-buffered saline supplemented with phenylmethylsulfonyl fluoride. Cells were lysed, homogenized, and enzymatically sheared with a subsequent immunoprecipitation using ER␣ antibodies (Santa Cruz Biotechnology) or control IgG (negative control). The resulting immunoprecipitates were subjected to PCR using a primer set ( Table 1 ) that amplifies a 305-bp fragment of CYP2C19 promoter encompassing the putative ERE half-site at position Ϫ151/ Ϫ147. The PCR was carried out for 35 cycles at an annealing temperature of 58°C. Quantitative evaluation of the PCR products was done by real-time PCR on the 7500 Fast Real-Time PCR system using a custom TaqMan Gene Expression assay (Applied Biosystems, Foster City, CA). The assay was constructed and validated by Applied Biosystems using the same proximal promoter fragment as a template.
Establishment of CYP2C19 Stable Cell Line. The Flp-In system (Invitrogen) was used for the construction of the stable cell line expressing CYP2C19. Cells were maintained in high-glucose Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen) at 37°C in a humidified atmosphere with 5% CO 2 . Before transfections, Zeocin (Invitrogen) was added to the cell culture medium at a final concentration of 100 g/ml. CYP2C19 cDNA was inserted into the pcDNA5/FRT plasmid and used in transfections of Flp-In-293 cells. The CYP2C19-pcDNA5/FRT plasmid was cotransfected with the Flp recombinase expression plasmid pOG44 using Lipofectamine 2000 (Invitrogen) according to manufacturer's protocol. Single colonies resistant to hygromycin B (Invitrogen) were selected and subcultured. Selection of positive clones was performed by detection of CYP2C19 mRNA and enzyme activity as described below. Mock cells were transfected with pcDNA5/FRT and pOG44 plasmids and prepared as described above.
Hormone Treatment of Human Hepatocytes. Human hepatocytes were obtained from CellzDirect/Invitrogen. Cells were seeded into 24-well plates at 10 5 cells/well using Williams' Medium E without Phenol Red supplemented with fetal bovine serum, plating cocktail solution, and dexamethasone. After 5 h, cells were treated with EE and ETE at concentrations of 10 Ϫ10 to 10 Ϫ6 M using ethanol as vehicle. Cells were maintained in estrogen treatment for 24 h until harvesting.
Detection of mRNA by RT-PCR. Total RNA was isolated from cultured Flp-In-293/CYP2C19 cells or from human hepatocytes with RNeasy Mini Kit (QIAGEN, Valencia, CA) according to the manufacturer's protocol. cDNA was prepared from the extracted RNA Fig. 2 . ER␣ interacts with oligonucleotides containing ERE half-site motifs. EMSA was performed with a double-stranded oligonucleotide (Table 1) comprising the putative ERE half-site I (Ϫ151/Ϫ147). This oligonucleotide formed a positive DNA-protein-complex with nuclear extract from HepG2 (A, lane 2, white arrow) or Huh7 cells (B, lane 1, white arrow). Competition experiments were performed with the respective nonlabeled wild-type oligonucleotide (A, lanes 3 and 4; B, lanes 2 and 3) and an oligonucleotide comprising a representative ERE consensus sequence (Higashi et al., 2007) , (A, lanes 5 and 6; B, lanes 4 and 5). Supershifts were observed with both HepG2 and Huh-7 NE at ERE half-site I using ER␣ antibody (indicated by black arrows; A, lane 8; B, lane 7). No band shifts were generated with ER␤ antibody (A, lane 9; B, lane 8). Ϫ, control incubation without labeled oligonucleotide; C, DNAprotein complex; Comp, competition reactions with wild-type oligonucleotide; ERE cons, competition reactions using an oligonucleotide carrying a representative ERE consensus sequence; 2C19 mut oligo, oligonucleotide with destructive mutations in ERE half-site I; anti-ER␣ and anti-ER␤, antibodies against the respective receptors.
Estradiol Receptor ␣ Regulates CYP2C19 Expression 889 at ASPET Journals on June 19, 2017 molpharm.aspetjournals.org using reverse transcriptase reaction with SuperScript II RT (Invitrogen). mRNA levels of pcDNA5/FRT-CYP2C19 cells or human hepatocytes were determined by quantitative PCR on a 7500 fast real-time PCR system using SYBR Green (Applied Biosystems) approach with the following CYP2C19-specific primer set: forward, 5Ј-GAAAAATT-GAATGAAAACATCAGGATTG; reverse, 5Ј-CGAGGGTTGTTGAT-GTCCATC. As internal control, TBP mRNA levels were codetermined using the primer pair 5Ј-GAA ACG CCG AAT ATA ATC CCA (forward) and 3Ј-GCT GGA AAA CCC AAC TTC TG (reverse).
Detection of Enzyme Activity by P450-Glo Assay. Flp-In-293/CYP2C19 cells were seeded in 96-well plates, and measurements were made at approximately 80% confluence. Cells were incubated with 20 M Luciferin-H EGE, a CYP2C19 substrate, for 30 min at 37°C. Inhibitors were added to cells 5 min before substrate incubation. Luminescence produced was proportional to CYP2C19 activity and was measured in the cell medium according to manufacturer's protocol (P450 Glo Assay; Promega) using a TD-20/20 Luminometer (Turner Designs, Sunnyvale, CA).
CYP2C19 Enzyme Activity in Microsomes. CYP2C19 enzyme activity and IC 50 were measured in the microsomes from the insect cells overexpressing CYP2C19 using the CYP2C19/CEC High Throughput Inhibitor Screening Kit (BD Biosciences, San Jose, CA).
Statistical Analysis. Statistical differences in reporter gene activity among CYP2C19 promoter constructs and in mRNA levels in human hepatocytes were determined by one sample t test using Prism (ver. 5.00 for Windows; GraphPad Software, San Diego, CA). A P value threshold of 0.05 was considered statistically significant in all analyses.
Results

ER␣ Binds Specifically to an ERE Half-Site Located
at ؊151/؊147 in the CYP2C19 promoter. Analysis of the first 1.8 kb of CYP2C19 promoter revealed four different putative ERE half-sites at positions (Ϫ151/Ϫ147), (Ϫ1117/ Ϫ1113), (Ϫ1515/1511), and (Ϫ1611/Ϫ1607) (Fig. 1A) . We tested by way of EMSA whether ER␣ or ER␤ could interact with any of these sites. Four different 32 P-labeled double stranded oligonucleotides (Table 1) carrying putative ERE half-sites were incubated with nuclear extracts from Huh-7 cells and HepG2 cells. A specific protein-DNA complex was formed only with oligonucleotide 2C19_wt_site I using both HepG2 (Fig. 2A, lane 2) and Huh-7 cell nuclear extracts (Fig.  2B, lane 1) . No specific complexes were observed with oligonucleotides 2C19_wt_site II to IV (data not shown). The migration of site I-specific complex was shifted using an antibody against ER␣ (Fig. 2, A, lane 8, and B, lane 7 ). An antibody against ER␤, however, failed to produce any band shifts, confirming that ER␤, which recognizes the same consensus sequence as ER␣, does not bind to ERE half-site I (Fig. 2, A, lane 9, and B, lane 8) . The specificity of the protein/DNA complex at locus Ϫ151/Ϫ147 (site I) was confirmed in competition experiments using nonlabeled oligonucleotides and also oligonucleotide comprising an ERE consensus cis-element (Fig. 2, A and B) . Moreover, no or reduced specific binding activity could be observed after incubation of nuclear extracts from Huh-7 cells or HepG2 cells with oligonucleotides mutated at the hypothetical ER␣ binding halfsite I (Fig. 2, A and B) . ER␣ interaction with the CYP2C19 promoter was also confirmed in EMSA experiments in which the labeled oligonucleotide 2C19_wt_site I was incubated with the in vitro-translated receptor (results shown in the supplement). Overall, these results suggest that ER␣ but not ER␤ is capable of binding to the potential ERE site at the position Ϫ151/Ϫ147 of CYP2C19 promoter.
Estradiol and 17␣-Ethinylestradiol Inhibit CYP2C19
Promoter Activity via the ER␣ Dependent Transactivation. The functional interaction of ER␣ with the CYP2C19 promoter was evaluated using reporter plasmids transfected into human hepatoma Huh-7 cells. A plasmid construct carrying 1.6 kb of the CYP2C19 promoter (Fig. 1B) , upstream of the reporter luciferase gene, was transiently transfected together with ER␣ expression vector and the cells were treated with increasing amounts of the ER␣ ligands ETE, EE, 4-OHT, or R. The results shown in Fig. 3 demonstrate a strong and dose-dependent down-regulation of reporter luciferase activity upon treatment with EE or ETE. The halfmaximal inhibitory effect of EE and ETE was observed at 10 Ϫ7 and 10 Ϫ8 M, respectively, and the extent of inhibition at 10 Ϫ6 M was approximately 70% using both steroids. Contrary to these results, 4-OHT and R were unable to affect the CYP2C19 promoter activity in this system (data not shown).
To investigate whether the ERE half-site I is indeed responsible for the observed estrogen-dependent down-regula- tion of CYP2C19 promoter activity, as suggested by EMSA experiments, a luciferase construct carrying a mutant form of ERE half-site I (Fig. 1B) was tested in the gene reporter experimental setup using ER␣ ligands at the highest effective concentration (10 Ϫ6 M). As shown in Fig. 4 , the inhibitory effect of EE and ETE was partly abolished upon transfection of the mutated construct. These results support the hypothesis of a ligand-activated ER␣ effect in the suppression of CYP2C19 promoter.
Estradiol and 17␣-Ethinylestradiol Suppress CYP2C19 mRNA Expression in Hepatocytes. To further examine the effects of estrogen derivatives on hepatic CYP2C19 expression, we determined the CYP2C19 mRNA levels in dependence of estradiol or 17␣-ethinylestradiol treatments using three different batches of human hepatocytes. Cells were either treated with vehicle (ethanol), EE, or ETE. As shown in Fig. 5 , real-time RT-PCR revealed that CYP2C19 mRNA levels were significantly suppressed by treatments with EE at concentrations of 10 Ϫ7 M. The effect of EE was found to be stronger compared with the effect seen with ETE. These results show that estrogen derivatives are indeed able to significantly inhibit CYP2C19 expression in human hepatocytes, most likely via the proposed ER␣-dependent promoter-regulatory pathway, although one has to bear in mind that during cultivation, the hepatocytes lose their ability to express P450s and the system might not be optimal for this reason.
ER␣ Is Associated with CYP2C19 Promoter in Huh-7 Cells. EMSA analysis and gene reporter data suggest that CYP2C19 expression might be regulated by ER-dependent Fig. 4 . Mutation in the ERE half-site I partly abolishes the inhibitory effects of ETE and EE on the luciferase activity of CYP2C19 promoter construct in Huh-7 cells. Relative luciferase activities of Ϫ1.6-kb CYP2C19 promoter fragment subcloned into pGL3basic vector. Data are shown as fold changes of luciferase activity of the construct mutated at ERE half-site I relative to the activity of the wild-type construct after cotransfection with pcDNA3.1-ER␣ or mock (pcDNA3. 6 . ER␣ is associated with CYP2C19 promoter at ERE half-site I in Huh7 cells. ER␣ binding to CYP2C19 promoter was analyzed using ChIP assay. Top, immune complexes generated by anti-ER␣ and control IgG were PCR-amplified (35 cycles) using the primer set for ChIP (indicated in Table 1 and Fig. 1B) targeting ERE half-site I in CYP2C19 promoter. Agarose gel electrophoresis of PCR products demonstrates a predicted amplicon size of approximately 300 bp. Bottom, real-time PCR using the same template as above and a standard cycling program suggested by Applied Biosystems for the amplifications with TaqMan probes (Materials and Methods). Results are expressed as a difference between the C t (cycle threshold) for the PCR product from the control IgG immunoprecipitate and anti-ER␣ immunoprecipitate (target). Input is a positive PCR control (same fragments amplified from the starting material before the immunoprecipitation). V, vehicle; IP, immunoprecipitation.
Estradiol Receptor ␣ Regulates CYP2C19 Expression 891 at ASPET Journals on June 19, 2017 molpharm.aspetjournals.org transcriptional mechanisms. To investigate whether ER␣ is indeed associated with the putative cis-element in CYP2C19 promoter and whether ER ligands could enhance such binding as it occurs in the classic scenario of the nuclear receptor mediated modulation of transcriptional activity, we used the advantage of the ChIP technology. Genomic DNA from intact Huh-7 cells, which were either not treated or treated with ETE or 4-OHT, was isolated, cross-linked, sonicated, and immunoprecipitated with ER␣ antibody. The resulting DNA fragments were amplified by PCR using a primer set encompassing ERE half-site I at position (Ϫ151/Ϫ147) ( Table 1, Fig.  1A ). As shown in Fig. 6 , top, the primer set generates a PCR product of the predicted size with DNA from vehicle and ETE-treated cells, whereas the 4-OHT treatment resulted in the loss of the band. These results were quantitatively supported by real-time PCR using a custom-made TaqMan assay that was constructed on the basis of the same promoter fragment (Fig. 6, bottom) . The amount of PCR product from the ETE-treated cells was 2.3-fold higher compared with the control (vehicle) with negligible amounts detected in the 4-OHT-treated cells. This is consistent with the EMSA results that demonstrated interaction of the ERE oligonucleotides with the nuclear ER␣ from the intact cells. Stimulation of Huh-7 cells with ETE resulted in the 2.3-fold increase of the PCR product (Fig. 6 ). It is noteworthy that the 4-OHT treatment apparently abolishes the ER␣ binding as judged by the sharp drop in the amount of the expected PCR product. These results are in good agreement with the gene reporter and EMSA data indicating that ER␣ may indeed interact with CYP2C19 promoter in vivo and that this binding is regulated by ER ligands.
High Concentrations of ETE and EE Directly Inhibit CYP2C19 Enzyme Activity. Clinical data on the lower activity of CYP2C19 in women using OCs were previously interpreted as a direct inhibitory action of steroids on the CYP2C19 enzyme (Laine et al., 2000) . To investigate such a scenario, we tested the effects of ETE and EE on CYP2C19 activity in human embryonic kidney 293 cells stably expressing CYP2C19. CYP2C19 expression was confirmed by both the mRNA (results not shown) and enzyme activity levels (Fig. 7, A and B) . EE and ETE were found to inhibit CYP2C19 activity with IC 50 values of 16 and 6.0 M, respectively, as shown on Fig. 7C . This effect was confirmed by using CYP2C19 inhibitor screening kit from BD Biosciences. IC 50 measurements using microsomes from insect cells overexpressing CYP2C19 showed lower levels (0.6 and 0.4 M for ETE and EE, respectively; Fig. 7D ), which might be connected with the better availability of inhibitors. However, both in cells and in the recombinant system, these values are 1 to 2 orders of magnitude higher compared with the abovementioned data on the transcriptional effects of steroids.
Discussion
In the present study, we present evidence for that estrogen receptor ␣, activated by its ligands EE and ETE, is able to inhibit CYP2C19 expression via a newly identified ERE binding half-site at position (Ϫ151/Ϫ147) in the CYP2C19 promoter. This is the first study showing that estradiol and its derivatives are able to modulate CYP2C19 promoter activity, and this occurs via the classic ERE-dependent pathway. Hence, our data suggest a novel molecular mechanism for the inhibitory effect of ETE on CYP2C19 activity that has been observed in several clinical studies (Palovaara et al., 2003; Shelepova et al., 2005) . This effect has been previously explained by a competitive inhibition at the active site of the enzyme (Laine et al., 2000) .
In silico analysis of the first 1.8 kb of the 5Ј-upstream region of the CYP2C19 gene revealed four putative ERE half-sites. Although ER␤ did not bind to any of the hypothetical ERE consensus sequences, which showed protein binding in EMSA analysis, a specific binding of ER␣ to CYP2C19 promoter at position (Ϫ151/Ϫ147) was confirmed by both EMSA and ChIP analysis using Huh-7 cells. It is known that estrogen receptor ␣ and ␤ mediate their effects through at least four different pathways. In the socalled classic estrogen-dependent pathway, the hormone binds to the ER leading to conformational changes and dimerization of the receptor, which allows an interaction with comodulators and an eventual binding of ligand-receptor complex to the specific EREs in the regulatory regions of target genes (McDevitt et al., 2008) . In addition, there are three other known mechanisms of ER activation, including second-messenger-dependent regulation of a membrane-associated ER and interaction with other transcription factors (McDevitt et al., 2008; Safe and Kim, 2008) . Our results, especially those obtained in EMSA and ChIP, strongly support the important role of the classic regulatory pathway of estrogen-dependent CYP2C19 gene regulation. However, the destructive mutations in ERE half-site I were only partly able to abolish the inhibitory effects of ETE and EE using the reporter constructs in Huh-7 cells (see Figure 4) . Therefore, we cannot completely exclude the possibility that other nonclassic ER-dependent pathways may also play a role in CYP2C19 regulation or that other, as-yet-detected ERE sites are also involved in the estrogen dependent regulation of CYP2C19.
CYP2C19 is not the only enzyme of the cytochrome P450 family that is known to be influenced by female sex steroids. For example, CYP2C9, which is very important for metabolism and dosing of, for example, warfarin and antiepileptics, is strongly inhibited by estrogen derivates Sandberg et al., 2004) . Indeed comparative sequencing analysis of the CYP2C9 promoter revealed that this enzyme carries an ERE similar to that identified here in the CYP2C19 gene, and it might be that the same mechanism is also relevant for estrogen-dependent CYP2C9 inhibition as here described for CYP2C19. In contrast, Benowitz et al. (2006) reported a significantly higher metabolism rate for the CYP2A6 substrates nicotine and cotinine in women compared with men and especially in women taking OCs. Similar results were obtained by Higashi et al. (2007) , who proved experimentally that EE is able to induce CYP2A6 via an ERE element in CYP2A6 promoter. The modulatory factors determining enhanced or decreased promoter activity of the P450 genes in response to ER have to be identified. Our findings of an inhibitory effect of estrogens on CYP2C19 are well in line with earlier in vivo reports showing clinically relevant decreased metabolism of CYP2C19-specific substrates in women who regularly take pills that contain estradiol derivatives. This thus leads to important pharmacokinetic drugdrug interactions with other CYP2C19 substrates (Zhang et al., 2007) .
As mentioned, it has been proposed that estrogen-dependent CYP2C19 inhibition may occur as a result of the competitive action of ETE on CYP2C19 enzyme (Laine et al., 2000 . Here we have shown that ETE and EE indeed have the potential to directly inhibit CYP2C19 enzyme activity in intact cells overexpressing CYP2C19 or in microsomes but at much higher concentrations than required for transcriptional inhibition. These results are well in line with earlier observations (Laine et al., 2000 showing an effective in vitro inhibition of omeprazole 5-hydroxylation only at very high EE concentrations (Ͼ10 Ϫ6 M). In contrast, transcriptional inhibition of CYP2C19 expression, as shown in this study, was exerted at much lower concentrations of EE and ETE, with IC 50 at 10 Ϫ7 to 10 Ϫ8 M in luciferase gene reporter assay and maximum inhibitory effects on CYP2C19 mRNA levels at 10 Ϫ7 M in human hepatocytes. This indicates that the mechanisms of OC-dependent inhibition of CYP2C19 activity in vivo would mainly be exerted by inhibition of CYP2C19 gene transcription rather than by competitive inhibition, and the results indicate for the first time an estrogendependent transcriptional regulation of this gene.
In conclusion, our results suggest a new regulatory mechanism by which exogenous estrogen derivatives unfold their inhibitory potential on CYP2C19. It could be also suggested that similar molecular mechanisms underlie the known inhibitory effects of female sex steroids on the activity of other cytochrome P450s (e.g., CYP2C9) Sandberg et al., 2004) .
